FY2023 EPS Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreased by Jefferies Financial Group

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Jefferies Financial Group reduced their FY2023 earnings per share estimates for BioCryst Pharmaceuticals in a research note issued on Wednesday, November 6th. Jefferies Financial Group analyst M. Raycroft now expects that the biotechnology company will post earnings of $0.14 per share for the year, down from their prior forecast of $0.24.

Several other research firms have also recently issued reports on BCRX. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. ValuEngine cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, October 31st. Needham & Company LLC restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday. Finally, BidaskClub cut shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 4th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $9.64.

BioCryst Pharmaceuticals stock traded down $0.03 during midday trading on Friday, hitting $2.03. 1,337,600 shares of the stock were exchanged, compared to its average volume of 1,473,949. BioCryst Pharmaceuticals has a fifty-two week low of $1.95 and a fifty-two week high of $9.95. The stock has a market capitalization of $224.19 million, a price-to-earnings ratio of -2.07 and a beta of 1.86. The stock’s 50-day simple moving average is $2.53 and its 200 day simple moving average is $3.71. The company has a current ratio of 1.44, a quick ratio of 1.43 and a debt-to-equity ratio of 2.38.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 371.33% and a negative net margin of 1,091.44%. The firm had revenue of $1.78 million for the quarter, compared to analyst estimates of $4.54 million.

Several institutional investors and hedge funds have recently made changes to their positions in BCRX. Bank of Montreal Can increased its position in shares of BioCryst Pharmaceuticals by 921.9% during the second quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 9,219 shares during the last quarter. Quantamental Technologies LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $43,000. Jane Street Group LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $69,000. Cubist Systematic Strategies LLC increased its position in shares of BioCryst Pharmaceuticals by 143.6% during the second quarter. Cubist Systematic Strategies LLC now owns 27,016 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 15,924 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC increased its position in shares of BioCryst Pharmaceuticals by 297.3% during the second quarter. Quantitative Systematic Strategies LLC now owns 43,590 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 32,618 shares during the last quarter. Institutional investors and hedge funds own 90.67% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Featured Story: Technical Analysis of Stocks, How Can It Help

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply